Publications
5808 Results
- Journal / Conference
- British Journal of Haematology 165(4):497-503;
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID24528179
- PMC
- PMC4064464
- Study Number(s)
- S0521
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
- Journal / Conference
- Blood 123(1):78-85;
- Year
- 2014
- Research Committee(s)
- Myeloma
- PMID
- PMID24144643
- PMC
- PMC3879908
- Study Number(s)
- S0120
Clinical, genomic and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
- Journal / Conference
- Cancer 120(19):2980-2985
- Year
- 2014
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID25041791
- PMC
- PMC4284963
- Study Number(s)
- S0727
Dual blockade of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
- Journal / Conference
- Journal of Clinical Oncology 32(23):2463-2470;
- Year
- 2014
- Research Committee(s)
- Lung
- PMID
- PMID25002722
- PMC
- PMC4121504
- Study Number(s)
- S0802
SWOG S0802: a randomized phase II trial of weekly topotecan with and without afilbercept in patients with platinum-treated extensive state small cell lung cancer
- Journal / Conference
- British Journal of Haematology 164(2):223-32;
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID24383843
- PMC
- PMC4127316
- Study Number(s)
- S0325
Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized phase II trial in newly diagnosed chronic phase chronic myeloid leukemia
- Journal / Conference
- Leukemia Research 38(3):329-333;
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID24411921
- PMC
- PMC4247790
- Study Number(s)
- S0432
Four Different Regimens of Farnesyltransferase Inhibitor Tipifarnib in Older, Untreated Acute Myeloid Leukemia Patients: North American Intergroup Phase II study SWOG S0432
- Journal / Conference
- Lancet Oncology 15(4):474-482;
- Year
- 2014
- Research Committee(s)
- Breast and Cancer Survivorship
- PMID
- PMID24636210
- PMC
- PMC4352316
Effects of adjuvant exemestane versus anastrozole on bone mineral density in women with early breast cancer: a companion study to NCIC CTG MA.27
- Journal / Conference
- Head & Neck 36(12):1712-1717
- Year
- 2014
- Research Committee(s)
- Head and Neck
- PMID
- PMID24166832
- PMC
- PMC4640463
- Study Number(s)
- S0329
A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): SWOG study S0329
- Journal / Conference
- Leukemia 28(2):289-292;
- Year
- 2014
- Research Committee(s)
- Leukemia
- PMID
- PMID23760400
- PMC
- PMC4457325
- Study Number(s)
- S0106, S0112, SWOG-8600, SWOG-9031, SWOG-9126, SWOG-9333, SWOG-9500, S9617, S9918
Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson
- Journal / Conference
- Cancer Prevention Research 27(9):886-895;
- Year
- 2014
- Research Committee(s)
- Prevention, Screening, and and Surveillance
- PMID
- PMID24961880
- PMC
- PMC4408535
- Study Number(s)
- S0000